Cargando…
Anti-Tumour Effects of a Specific Anti-ADAM17 Antibody in an Ovarian Cancer Model In Vivo
ADAM 17 (TNF-α converting enzyme, TACE) is a potential target for cancer therapy, but the small molecule inhibitors reported to date are not specific to this ADAM family member. This membrane-bound metalloproteinase is responsible for ectodomain shedding of pathologically significant substrates incl...
Autores principales: | Richards, Frances M., Tape, Christopher J., Jodrell, Duncan I., Murphy, Gillian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394719/ https://www.ncbi.nlm.nih.gov/pubmed/22792380 http://dx.doi.org/10.1371/journal.pone.0040597 |
Ejemplares similares
-
Targeting the Sheddase Activity of ADAM17 by an Anti-ADAM17 Antibody D1(A12) Inhibits Head and Neck Squamous Cell Carcinoma Cell Proliferation and Motility via Blockage of Bradykinin Induced HERs Transactivation
por: Huang, Yanchao, et al.
Publicado: (2014) -
Novel structured ADAM17 small-molecule inhibitor represses ADAM17/Notch pathway activation and the NSCLC cells’ resistance to anti-tumour drugs
por: Chi, Meng, et al.
Publicado: (2023) -
Anti-Tumour Efficacy of Capecitabine in a Genetically Engineered Mouse Model of Pancreatic Cancer
por: Courtin, Aurélie, et al.
Publicado: (2013) -
Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells
por: Caiazza, F, et al.
Publicado: (2015) -
ADAM17 inhibition enhances platinum efficiency in ovarian cancer
por: Hedemann, Nina, et al.
Publicado: (2018)